Format

Send to

Choose Destination
Cell Death Dis. 2015 Oct 15;6:e1914. doi: 10.1038/cddis.2015.242.

Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.

Author information

1
Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
2
Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuou-ku, Chiba 260-8717, Japan.
3
Innovative Therapy Research Group, Nihon University Research Institute of Medical Science, Nihon University School of Medicine, 30-1 Oyaguchi-Kamicho, Itabashi, Tokyo 173-8610, Japan.
PMID:
26469963
PMCID:
PMC4632284
DOI:
10.1038/cddis.2015.242
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center